Clinical evaluation is basis for deciding whether additional imaging is needed
Cheryl Guttman Krader
Latanoprostene bunod especially useful to patients who do not respond to first-line therapy
Research to understand underlying mechanisms may lead to clues for targeted therapy
Investigators optimistic about sustained-release ranibizumab delivery based on phase II LADDER study
Ophthalmology benefiting from active programs for innovative product development in 2018 and onward
Surgeon provides overview of recent developments, applications with technology
Results from the 36-month Hyperopia Treatment Study 1 (HTS1) comparing immediate versus delayed spectacle treatment for moderate hyperopia in children 1 to <3 years of age are consistent with showing a small to moderate benefit or no b
The use of eye drops as a treatment for glaucoma will likely become rare considering the pace of progress in developing alternative drug delivery systems, said James D. Brandt, MD, to attendees of the 2018 Glaucoma Subspecialty Day.
The history of commercialization of ophthalmic optical coherence tomography (OCT) is a fascinating story considering its evolution and how the technology moved so rapidly from the laboratory into the clinic, according to Jay S.
Orbital and adnexal anatomy and pathology can affect IOP and its measurement as well as planning of glaucoma surgery, and these structures can be affected by medical and surgical treatment of glaucoma